APPLICATION: BEST PRACTICES 1
Abbreviatedas CHD, the Coronary heart disease encompasses waxy substancesreferred to as the plaque piles up inside the coronary arteries. Thecoronary arteries are known to supply blood rich in oxygen to theheart muscle, and when plaque piles up in them, the condition isregarded as atherosclerosis. The piling up has been reported to occurover an extended period. As time elapses, plaque can rupture orharden. The hardened plaque causes the narrowing of the coronaryartery leading to a reduction in the flow of full blood of oxygen tothe heart. In case the plaque breaks, a blood clot can be formed onthe surface of the coronary artery. A large clot can entirely ormostly block the flow of blood through the coronary artery. Theruptured plaque equally narrows and hardens the coronary artery withtime (National Institute of Health, 2016). Studieshave been determined the best practices for assessing as well asmanaging coronary heart disease. A universal conclusion from themajority of the studies regards the fact that there are no finalguidelines about the management of coronary heart disease. Theselected study by Maddox et al. (2014) agrees with this conclusionbut presents some of the best practices for managing coronary heartdisease. These include understanding the best practices forquantifying CAD (coronary artery disease), risk characterization, aswell as bets risk mitigation methods. The practices also coverconducting randomized trials of the therapies like statin andantiplatelet agents using clearly defined CAD (Maddox et al., 2014). Incomparison, the current best practices presented in the WHI articleinclude individual treatment, utilizing the lowest effective dosewith an aim of realizing the benefits and avoiding the side effects,and considering minimizing the treatment duration (Rossouw et al.,2013). The practice suggested in the study by Maddox et al. (2014) toperiodically undertake randomized trials of the therapies aligns withthe use of the lowest effective doses since both aims at reducing therisk and avoiding the side effects. The annual reassessment of theration of the benefit accrued to risk involved and mirrors the needto understand the risk mitigation methods. Inconclusion, this paper holds the thought that the present bestpractices in the selected article need to be included in clinicalpractice. In order to avoid the side effects of most therapies, theclinical trials present the best option for gathering evidence-baseddata. The studies by WHI have demonstrated this over time andinformed clinical practice (Gurney et al., 2014).ReferencesGurneyy,E. P., Nachtiqall, M., Nachtiqall, L., & Naftolin, F. (2014). Thewomen`s health initiative trial and related studies: 10 years later:a clinician`s view. TheJournal of Steroid Biochemistry and Molecular Biology, 142,4-11. Maddox,T., Stanislawski, M., Grunwald, G., Bradley, S., & Ho, M. (2014).Nonobstructivecoronary artery disease and risk of myocardial infarction.TheJournalof American Medical Association 312(17),1754-1763.NationalInstitute of Health. (2016). WhatIs coronary heart disease?Retrieved fromhttp://www.nhlbi.nih.gov/health/health-topics/topics/cadRossouw,J., Manson, J., Kaunitz, A., & Anderson, G. (2013). Lessonslearned from the Women’s Health Initiative Trials of MenopausalHormone Therapy. ObstetGynecology, 121(1), 172-176.